Key result
Proposed statistical designs and methods for prevalence estimation under group testing can address mis-substitution bias when assay sensitivity and specificity are unknown.
The study provides statistical methods to correct for mis-substitution bias in disease prevalence estimation under group testing when assay accuracy is unknown.
Answers are grounded in this paper and cite their sources.
May facilitate accurate prevalence estimation in group testing with unknown assay accuracy; leaves open real-world validation before clinical adoption.
We consider the problem of estimating the prevalence of a disease under a group testing framework. Because assays are usually imperfect, misclassification of disease status is a major challenge in prevalence estimation. To account for possible misclassification, it is usually assumed that the sensitivity and specificity of the assay are known and independent of the group size. This assumption is often questionable, and substitution of incorrect values of an assay's sensitivity and specificity can result in a large bias in the prevalence estimate, which we refer to as the mis-substitution bias. In this article, we propose simple designs and methods for prevalence estimation that do not require known values of assay sensitivity and specificity. If a gold standard test is available, it can be applied to a validation subsample to yield information on the imperfect assay's sensitivity and specificity. When a gold standard is unavailable, it is possible to estimate assay sensitivity and specificity, either as unknown constants or as specified functions of the group size, from group testing data with varying group size. We develop methods for estimating parameters and for finding or approximating optimal designs, and perform extensive simulation experiments to evaluate and compare the different designs. An example concerning human immunodeficiency virus infection is used to illustrate the validation subsample design.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2014) studied Human immunodeficiency virus infection (example). Prevalence estimation methods without known assay sensitivity and specificity vs. Standard methods assuming known sensitivity and specificity was evaluated on Prevalence estimation accuracy and bias reduction. Proposed statistical designs and methods for prevalence estimation under group testing can address mis-substitution bias when assay sensitivity and specificity are unknown.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: